Session Title: Free Paper Session 10: Uveitis
Session Date/Time: Friday 08/09/2017 | 11:00-12:30
Paper Time: 12:00
Venue: Room 111
First Author: : L.Weber GERMANY
Co Author(s): : S. Marx G. Auffarth S. Sel A. Scheuerle T. Tandogan R. Khoramnia
To evaluate the safety and efficacy of Iluvien (fluocinolone acetonide intravitreal implant 0.19 mg) in the treatment of non-infectious uveitic macular edema.
University Eye Clinic Heidelberg, Heidelberg, Germany
Data from 8 patients (11 eyes) with non-infectious uveitic macular edema who were treated with intravitreal injection of 0.19 mg fluocinolone acetonide intravitreal implant were reviewed in an on-going clinical trial. Main outcome measures were changes in central retinal thickness (CRT) in optical coherence tomography (OCT) and changes in best-corrected distance visual acuity (CDVA). Median follow-up was 17 months (range: from 4 to 40 months).
In the first follow-up after 1 to 4 months, 10 eyes showed a decrease of the CRT (median decrease: 56 µm). In 7 eyes, OCT showed a completely dry macula. 6 eyes showed an improvement in CDVA (3 eyes gained 1 line, 1 eye gained 3 lines, 1 eye gained 4 lines, 1 eye gained 8 lines). 3 eyes showed a reduction of 1 line despite of a reduction of CRT in OCT. Regarding safety, no eye showed an increase in intraocular pressure which required additional treatment. 10 eyes were pseudophakic prior to implantation of Iluvien. The only phacic patient did not require cataract surgery so far.
In this small case series of eyes, treatment with fluocinolone acetonide intravitreal implant for non-infectious uveitic macular edema was associated with a reduction of CRT, an improvement of the visual acuity and showed an acceptable safety profile.